Claim Ledger
42% answered
Did management answer the analysts?
12 analyst questions audited, 6 evaded or deflected.
View Claim Ledger →
Divi's Laboratories — Q1 FY26
Divis Laboratories reported a strong Q1 FY26 with PAT rising 26.7% YoY to INR 545 crore, driven by robust custom synthesis traction and backward integration benefits.
bullish
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Divis Laboratories reported a strong Q1 FY26 with PAT rising 26.7% YoY to INR 545 crore, driven by robust custom synthesis traction and backward integration benefits. Revenue grew 15.1% YoY to INR 2,529 crore (total income), with custom synthesis contributing 53% of sales. The company highlighted a healthy pipeline of RFPs and multiple projects advancing toward commercialization. Management guided for total capex of INR 2,000 crore for FY26, backed by long-term supply commitments. Key growth drivers include solid-phase peptide synthesis capacity for GLP-1 treatments and three major dedicated projects. However, generic pricing pressures persist, and geopolitical uncertainties (tariffs, Red Sea disruptions) remain risks. The Kakinada Unit 3 is already contributing to backward integration, freeing up GMP capacity for new molecules. Overall, the outlook is positive but tempered by regulatory timelines and macro headwinds.
डिविस लैबोरेटरीज ने पहली तिमाही (Q1 FY26) में शानदार नतीजे दिए। कंपनी का मुनाफा (PAT) 26.7% बढ़कर 545 करोड़ रुपये हो गया। इसकी वजह कस्टम सिंथेसिस (ग्राहकों के लिए खास केमिकल बनाना) का अच्छा कारोबार और खुद के कच्चे माल का उत्पादन (बैकवर्ड इंटीग्रेशन) है। कुल आय 15.1% बढ़कर 2,529 करोड़ रुपये रही, जिसमें कस्टम सिंथेसिस का हिस्सा 53% था। कंपनी ने कहा कि नए ऑर्डर (RFPs) अच्छे आ रहे हैं और कई प्रोजेक्ट बिक्री के करीब हैं। इस साल कंपनी 2,000 करोड़ रुपये निवेश (कैपेक्स) करेगी, जिसके लिए लंबे समय के ऑर्डर मिले हैं। GLP-1 दवाओं के लिए पेप्टाइड बनाने की नई क्षमता और तीन बड़े प्रोजेक्ट मुख्य वृद्धि के कारण हैं। हालांकि, जेनेरिक दवाओं की कीमतों पर दबाव और भू-राजनीतिक जोखिम (टैरिफ, लाल सागर में समस्या) बने हुए हैं। काकीनाडा यूनिट 3 से कच्चा माल बनाने में मदद मिल रही है। कुल मिलाकर, संभावनाएं अच्छी हैं, लेकिन नियमों और बाहरी चुनौतियों पर नजर रखनी हो
Promises0 met · 1 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
3 risks
Risk Intelligence
Generic Pricing Pressure Persists
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Custom Synthesis Revenue Share
53%
+3pp YoY
Custom synthesis contributed 53% of total revenue in Q1 FY26, up from 50% in the year-ago quarter, reflecting strong demand from innovators.
Capacity Utilization
80%
flat YoY
Capacity utilization remained at 80% in Q1 FY26, consistent with the prior year, indicating optimal operational efficiency.
Nutraceutical Revenue
INR 250 Cr
+40.4% YoY
Nutraceutical revenue grew 40.4% YoY to INR 250 crore, driven by steady demand recovery post-COVID.
Capital Work in Progress
INR 1,319 Cr
+INR 261 Cr QoQ
Capital work in progress increased to INR 1,319 crore as of June 30, 2025, reflecting ongoing capacity expansion projects.
What Changed vs Last Quarter
NEW
FY26 Capex Guidance of INR 2,000 Crore
Management guided for total capital expenditure of INR 2,000 crore in FY26, directed at strategic projects, capacity expansion, and technology upgrades.
NEW
Three Major Dedicated Projects with Long-Term Contracts
Three custom synthesis projects are underway with long-term supply commitments, expected to commercialize over the next 12-24 months.
NEW
Peptide Capacity Commercialization in 12-14 Months
Solid-phase peptide synthesis capacity is expected to commercialize within 12-14 months, subject to regulatory approvals and customer timelines.
DROPPED
Double-digit revenue growth in FY26
Management expects overall revenue to grow at a double-digit rate in FY26, driven by custom synthesis and generics.
DROPPED
Kakinada phase I completion with ₹200 crore additional spend
Phase I of Kakinada will require about ₹200 crore more in capex, with benefits expected to flow from FY26 onwards.
DROPPED
New CS contracts commercialization by late 2026/early 2027
The two long-term custom synthesis contracts announced are expected to start commercial production around Q3/Q4 2026 or early 2027, subject to regulatory approvals.
NEW RISK
Geopolitical and Tariff Uncertainty
Analysts raised concerns about U.S. tariffs and geopolitical disruptions (Red Sea) affecting logistics and costs; management noted lack of clarity and long-term contracts as mitigants.
NEW RISK
Regulatory Approval Timelines for New Capacities
Commercialization of Kakinada Unit 3 and peptide capacity depends on regulatory approvals, which could take 1-2 years, delaying revenue contribution.
RISK GONE
Red Sea disruptions impacting logistics
Extended lead times of 2-3 weeks due to Red Sea rerouting are increasing freight costs and complicating supply chain planning.
RISK GONE
Customer regulatory approval delays
Commercialization of new CS contracts depends on customer regulatory approvals, which could slip beyond the guided timeline.
RISK GONE
Inventory normalization uncertainty
Inventory remains elevated at ~₹3,000 crore; management could not confirm if this level will sustain, posing working capital risk.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY25, Q3 FY25, Q4 FY25
Extended lead times of 2-3 weeks due to Red Sea rerouting are increasing freight costs and complicating supply chain planning.
Mentioned in Q1 FY25, Q3 FY25, Q4 FY25
Management expects overall revenue to grow at a double-digit rate in FY26, driven by custom synthesis and generics.
Mentioned in Q1 FY25, Q2 FY25
Total capital expenditure for FY25, including Kakinada, is expected to be around INR 1,600 crores, with INR 1,000 crores remaining to be spent.
Mentioned in Q1 FY25, Q3 FY25
Ongoing price erosion in generics continues to pressure revenue growth despite volume increases.
Fast read
Guidance and risk preview
Management guided for total capital expenditure of INR 2,000 crore in FY26, directed at strategic projects, capacity expansion, and technology upgr...
Management acknowledged continued pricing pressure in the generic business, with no clear timeline for stabilization, impacting margins.
View Risks →